Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program

  • Cancer Discov. 2026 May 13. doi: 10.1158/2159-8290.CD-26-0542.
Chiara Maria Cattaneo  1 Sharon Scardellato  2 Gianluca Mauri  3 Vittoria Matafora  4 Veera K Ojala  5 Costanza Cannariato  6 Rosaria Chila  3 Zulma Irene Magnani  7 Wouter Scheper  8 Luca Lazzari  9 Emile E Voest  8 Maria Chiara Bonini  10 Angela Bachi  4 Salvatore Siena  11 Silvia Marsoni  12 Giovanni Germano  13 Alberto Bardelli  14
Affiliations
  • 1. IRCCS Humanitas Research Hospital Milano Italy.
  • 2. FIRC Institute of Molecular Oncology Milano, Milano Italy.
  • 3. FIRC Institute of Molecular Oncology Milan Italy.
  • 4. IFOM ETS - The AIRC Institute of Molecular Oncology Milan Italy.
  • 5. FIRC Institute of Molecular Oncology Italy.
  • 6. IRCCS Ospedale San Raffaele Italy.
  • 7. IRCCS Ospedale San Raffaele Milan Italy.
  • 8. Netherlands Cancer Institute Amsterdam Netherlands.
  • 9. IFOM ETS - The AIRC Institute of Molecular Oncology Milano, Milano Italy.
  • 10. IRCCS Ospedale San Raffaele Milano, Italy Italy.
  • 11. Università degli Studi di Milano, Niguarda Cancer Center Milan, Italy Italy.
  • 12. IFOM ETS Milan Italy.
  • 13. University of Milan Milano Italy.
  • 14. University of Turin Orbassano, TO Italy.
Abstract

While microsatellite-instable (MSI) colorectal cancers (CRC), reflecting mismatch repair deficiency, often respond to immune checkpoint inhibitors, microsatellite-stable (MSS) tumors remain largely resistant. This disparity is typically attributed to differences in neoantigen load. However, whether antigen-independent mechanisms contribute to immune evasion in MSS-CRC remains unclear. To address this, we engineered a model in which MSI- and MSS-CRC cells express identical levels of a defined antigen recognized by TCR-engineered T cells. Despite equivalent antigen presentation, MSS tumors exhibited impaired T-cell activation, reduced cytotoxicity, and resistance to killing. We linked this immune evasion to the MSS tumor secretome, which suppressed immune responses even in immunogenic MSI cells by impairing immune synapse formation. Surfaceome profiling by mass spectrometry identified glycosylation-dependent alterations that impair immune recognition. Our findings demonstrate that MSS-CRC evades immune attack via intrinsic secretome-driven mechanisms, independent of antigenicity. Targeting glycosylation-linked suppressive pathways may restore T-cell responsiveness and improve immunotherapy efficacy in MSS-CRC.

Products